Deep Track Capital, LP
Q1 2023 13F-HR Holdings
Net value change ($000)
+53,041
(2.2%)
New positions
14
Sold out positions
17
Turnover %
35.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Intra-Cellular Therapies, Inc. | 92,055 | NEW |
| ALKERMES PLC | 84,570 | NEW |
| REATA PHARMACEUTICALS INC | 66,281 | NEW |
| GPCR | 62,967 | NEW |
| PLRX | 57,529 | 171.7% |
| IONS | 55,748 | 122.4% |
| TVTX | 41,893 | 43.5% |
| PACB | 40,581 | NEW |
| GERN | 40,358 | 224.9% |
| DVAX | 37,525 | 151.5% |
Top Reduces (Value $000, Stocks/ETFs)
| ASND | -85,491 | -100.0% |
| SRPT | -68,450 | -100.0% |
| IMVT | -57,072 | -33.1% |
| Horizon Therapeutics Public Ltd Co | -56,900 | -100.0% |
| BDQM | -36,823 | -100.0% |
| BIIB | -27,470 | -33.1% |
| Allakos Inc. | -25,298 | -61.3% |
| ESPR | -24,920 | -100.0% |
| BCYC | -23,483 | -28.1% |
| 89bio, Inc. | -21,597 | -44.1% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
83,067
(3.4% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|